Fractyl Health, Inc. - Common Stock (GUTS)

Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company’s first-quarter 2026 earnings call. Chief Executive Officer Dr. Harith R

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Fractyl Health (NASDAQ: GUTS) released positive 6-month results from its REVEAL-1 study in obese patients who discontinued GLP-1 therapy.

Fractyl (GUTS) Q3 2025 Earnings Call Transcript

Discover the stocks with unexpected trading volume in today's session on the US markets.

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

Fractyl Health reports Q2 2025 net loss of $27.9M, missing EPS estimates. No revenue, but clinical progress in Revita and Rejuva programs. Stock dips amid investor concerns.